Group 1 - The company plans to globally offer 37.91 million shares, with 3.79 million shares available in Hong Kong and 34.12 million shares for international sale [1] - The subscription period is set from December 2 to December 5, with a maximum offer price of HKD 26.38 per share and an entry fee of approximately HKD 2,664.60 for a board lot of 100 shares [1] - The total expected fundraising amount is HKD 1 billion, with a net amount of HKD 922 million, which will be used for R&D and commercialization of core products, enhancing production capacity, and general corporate purposes [1] Group 2 - The company is a clinical-stage biotechnology firm focused on developing and providing recombinant biopharmaceuticals in China, utilizing synthetic biology technology to address complex diseases with limited treatment options [2] - The projected net profits for the company are expected to be -160 million yuan for 2023, -364 million yuan for 2024, and -183 million yuan for the first half of 2025 [2]
宝济药业-B拟全球发售3791.17万股 12月2日起招股
Zheng Quan Shi Bao Wang·2025-12-02 01:35